IGF-1 LR3 (Long R3 IGF-1) is a modified form of insulin-like growth factor 1. The modification involves substituting the glutamic acid at position 3 with arginine (R3) and adding a 13-amino acid extension at the N-terminus, creating a 83-residue peptide compared to native IGF-1’s 70 residues.
Reduced IGFBP Binding
The key functional consequence of these modifications is dramatically reduced binding affinity to insulin-like growth factor binding proteins (IGFBPs). Native IGF-1 circulates almost entirely bound to IGFBPs (>99%), which regulate its bioavailability. LR3 modification increases the fraction of unbound, bioactive peptide.
Receptor Interaction
Despite the structural modifications, IGF-1 LR3 retains full binding affinity for the IGF-1 receptor (IGF-1R). This combination of preserved receptor activation with reduced sequestration by binding proteins makes it a valuable research tool for studying IGF-1 signaling pathways.